• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inflammatory Remission in T2 Severe Asthma.

作者信息

Rial Manuel J, Domínguez-Ortega Javier

机构信息

Department of Allergy, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.

Department of Allergy, Hospital Universitario La Paz, Institute for Health Research, Madrid, Spain.

出版信息

Front Allergy. 2022 May 30;3:923083. doi: 10.3389/falgy.2022.923083. eCollection 2022.

DOI:10.3389/falgy.2022.923083
PMID:35769583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9234872/
Abstract
摘要

相似文献

1
Inflammatory Remission in T2 Severe Asthma.T2重度哮喘的炎症缓解
Front Allergy. 2022 May 30;3:923083. doi: 10.3389/falgy.2022.923083. eCollection 2022.
2
The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma.未选择的严重哮喘患者人群中 2 型炎症亚型的流行情况。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1267-1275. doi: 10.1016/j.jaip.2020.09.051. Epub 2020 Oct 8.
3
Variability of 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital.指导重度哮喘生物治疗的两种炎症标志物的变异性：来自一家三级医院的5年回顾性研究。
World Allergy Organ J. 2021 Sep 21;14(9):100547. doi: 10.1016/j.waojou.2021.100547. eCollection 2021 Sep.
4
Multidimensional Assessment of Asthma Identifies Clinically Relevant Phenotype Overlap: A Cross-Sectional Study.哮喘的多维评估可识别具有临床相关性的表型重叠：一项横断面研究。
J Allergy Clin Immunol Pract. 2021 Jan;9(1):349-362.e18. doi: 10.1016/j.jaip.2020.07.048. Epub 2020 Aug 11.
5
"T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin.在与血嗜酸性粒细胞、呼出气一氧化氮和血清嗜酸粒细胞阳离子蛋白相关的严重哮喘中，“T2 高”。
Eur Respir J. 2019 Jan 3;53(1). doi: 10.1183/13993003.00938-2018. Print 2019 Jan.
6
Diagnosis and Management of T2-High Asthma.T2 高气道炎症型哮喘的诊断与管理。
J Allergy Clin Immunol Pract. 2020 Feb;8(2):442-450. doi: 10.1016/j.jaip.2019.11.020.
7
Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma.抗T2生物制剂治疗对依赖泼尼松的成年哮喘患者肺部通气的MRI评估作用
Chest. 2020 Oct;158(4):1350-1360. doi: 10.1016/j.chest.2020.04.056. Epub 2020 May 16.
8
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.复合 2 型生物标志物策略与基于症状风险的算法调整重度哮喘患者皮质类固醇剂量：一项多中心、单盲、平行组、随机对照试验。
Lancet Respir Med. 2021 Jan;9(1):57-68. doi: 10.1016/S2213-2600(20)30397-0. Epub 2020 Sep 8.
9
Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.小气道功能障碍作为严重嗜酸性粒细胞性哮喘生物治疗临床反应的预测指标和标志物：一项纵向观察研究。
Respir Res. 2020 Oct 21;21(1):278. doi: 10.1186/s12931-020-01543-5.
10
Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function.2 型生物标志物在严重哮喘中的脱节；以 FeNO 作为加重预测指标，periostin 作为肺功能降低预测指标占主导地位。
Respir Med. 2018 Oct;143:31-38. doi: 10.1016/j.rmed.2018.08.005. Epub 2018 Aug 9.

引用本文的文献

1
Efficacy Assessment of Biological Treatments in Severe Asthma.重症哮喘生物治疗的疗效评估
J Clin Med. 2025 Jan 7;14(2):321. doi: 10.3390/jcm14020321.
2
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps.2 型炎症性疾病缓解：当前证据、未满足的需求以及慢性鼻-鼻窦炎伴鼻息肉缓解定义的建议。
Curr Allergy Asthma Rep. 2024 Jan;24(1):11-23. doi: 10.1007/s11882-023-01118-6. Epub 2023 Dec 12.
3
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.靶向白细胞介素 5/白细胞介素 5 受体的生物制剂诱导的重度哮喘缓解：一项多中心真实世界研究的结果。
Int J Mol Sci. 2023 Jan 27;24(3):2455. doi: 10.3390/ijms24032455.

本文引用的文献

1
Stopping continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study).停止或继续长期美泊利珠单抗治疗严重嗜酸性粒细胞性哮喘（COMET 研究）。
Eur Respir J. 2022 Jan 6;59(1). doi: 10.1183/13993003.00396-2021. Print 2022 Jan.
2
Pollen-Induced Allergic Asthma and Rhinoconjunctivitis: Differences in Outcome Between Seasonal and Nonseasonal Exposure to Allergens Under Real-Life Conditions (The LANDSCAPE Study).花粉诱导的变应性哮喘和鼻结膜炎：现实生活条件下季节性和非季节性接触变应原的结局差异（景观研究）
J Investig Allergol Clin Immunol. 2020;30(6):454-456. doi: 10.18176/jiaci.0544. Epub 2020 May 6.
3
An expert consensus framework for asthma remission as a treatment goal.哮喘缓解作为治疗目标的专家共识框架。
J Allergy Clin Immunol. 2020 Mar;145(3):757-765. doi: 10.1016/j.jaci.2019.12.006. Epub 2019 Dec 19.
4
A review on the pathophysiology of asthma remission.哮喘缓解的病理生理学研究综述。
Pharmacol Ther. 2019 Sep;201:8-24. doi: 10.1016/j.pharmthera.2019.05.002. Epub 2019 May 8.
5
Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.严重过敏性哮喘患儿停用奥马珠单抗：一项观察性真实世界研究。
Allergy. 2019 May;74(5):999-1003. doi: 10.1111/all.13678. Epub 2019 Jan 29.
6
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma.奥马珠单抗停药后在“真实世界”重度哮喘中的疗效持续时间。
Thorax. 2018 Aug;73(8):782-784. doi: 10.1136/thoraxjnl-2017-210017. Epub 2017 Oct 27.
7
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.全球、地区和国家慢性阻塞性肺疾病和哮喘的死亡、患病率、残疾调整生命年以及与残疾相关的生命年，1990-2015 年：2015 年全球疾病负担研究的系统分析。
Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16.
8
A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.一项评价长期治疗后奥马珠单抗持续应答的随机多中心研究。
J Allergy Clin Immunol. 2017 Jul;140(1):162-169.e2. doi: 10.1016/j.jaci.2016.08.054. Epub 2016 Nov 5.
9
A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study.成人哮喘的12年预后：塞伊奈约基成人哮喘研究。
Respir Med. 2016 Aug;117:223-9. doi: 10.1016/j.rmed.2016.06.017. Epub 2016 Jun 23.
10
Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy.哮喘的发病率与缓解情况：意大利哮喘自然史的回顾性研究
J Allergy Clin Immunol. 2002 Aug;110(2):228-35. doi: 10.1067/mai.2002.125600.